Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now? (Q36167778)

12 August 2017

Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now? (English)

1 reference

12 August 2017

0 references

1 reference

1 reference

Luís Lima

1

0 references

Lúcio L. Santos

object named as

Lúcio Santos

series ordinal

4

0 references

Mário Dinis-Ribeiro

object named as

Mário Dinis-Ribeiro

series ordinal

2

0 references

Adhemar Longatto-Filho

object named as

Adhemar Longatto-Filho

series ordinal

3

0 references

language of work or name

1 reference

7 August 2012

1 reference

12 August 2017

1 reference

12 August 2017

2012

1 reference

12 August 2017

232609

1 reference

Creative Commons Attribution 3.0 Unported

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Cancer-promoting tumor-associated macrophages: new vistas and open questions

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Tumor markers: from laboratory to clinical utility

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients

2 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus Calmette-Guerin (BCG) intravesical instillation therapy for superficial bladder cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420223

Prospective Evaluation of Ki–67 Labeling in Predicting the Recurrence and Progression of Superficial Bladder Transitional Cell Carcinoma

23 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F232609

Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers

21 January 2018

1 reference

12 December 2020

Urinary IL‐2 assay for monitoring intravesical bacillus Calmette‐Guérin response of superficial bladder cancer during induction course and maintenance therapy

1 reference

12 December 2020

[DNA ploidy determination with flow cytometry, Ki-67 index and overexpression of p53 protein in 121 T1 superficial bladder carcinomas. Retrospective studies. Part II: Prognostic value and usefulness in the indication for prophylactic treatment with

1 reference

12 December 2020

Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors

1 reference

12 December 2020

Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer

1 reference

12 December 2020

Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer

1 reference

12 December 2020

Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy

1 reference

12 December 2020

Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer

1 reference

12 December 2020

T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer

1 reference

12 December 2020

Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome

1 reference

12 December 2020

Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer

1 reference

12 December 2020

Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients

1 reference

12 December 2020

p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors

1 reference

12 December 2020

Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin

1 reference

12 December 2020

Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu�rin immunotherapy for carcinoma in situ of the bladder

1 reference

12 December 2020

Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder

1 reference

12 December 2020

Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer

1 reference

12 December 2020

Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors

1 reference

12 December 2020

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy

1 reference

12 December 2020

Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer

1 reference

12 December 2020

Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome

1 reference

12 December 2020

IL-8 -251 T > A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort

1 reference

12 December 2020

The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study

1 reference

12 December 2020

Urinary fibronectin levels in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer

1 reference

12 December 2020

NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer

1 reference

12 December 2020

Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin

1 reference

12 December 2020

Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer

1 reference

12 December 2020

Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India

1 reference

12 December 2020

Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression

1 reference

12 December 2020

[Prognostic value of E-cadherina, beta catenin, Ki-67 antigen and p53 protein in the superficial bladder tumors]

1 reference

12 December 2020

Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India

1 reference

12 December 2020

Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin

1 reference

12 December 2020

Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG

1 reference

12 December 2020

Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer

1 reference

12 December 2020

HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours

1 reference

12 December 2020

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy

1 reference

12 December 2020

Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation

1 reference

12 December 2020

p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy

1 reference

12 December 2020

Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy

1 reference

12 December 2020

The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients

1 reference

12 December 2020

Cyclin D3 gene amplification in bladder carcinoma in situ

1 reference

12 December 2020

The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2

1 reference

12 December 2020

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

1 reference

12 December 2020

DNA ploidy and immunomarking of bladder urothelial tumors before and after intravesical bacillus Calmette-Guérin treatment

1 reference

12 December 2020

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

1 reference

12 December 2020

Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours

1 reference

12 December 2020

XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy

1 reference

12 December 2020

Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/232609

1 reference

12 August 2017

1 reference

PMC publication ID

3420223

12 August 2017

PubMed publication ID

22919375

1 reference

PMC publication ID

3420223